November is Lung Cancer Awareness Month. Lung cancer is the most common cause of cancer death worldwide making up almost 25% of all cancer deaths. Every year, more people die of lung cancer than of colon, breast, and prostate cancers combined. In recent years, clinical research has led to significant breakthroughs in the treatment of lung cancer, giving hope to millions of patients worldwide. However, there is still some way to go to reduce deaths from this cancer. Cromos Pharma is proud to play its part in supporting clinical trials to test and develop innovative drugs and interventions for lung cancer.
Smoking is the most common cause of lung cancer. Other risk factors include genetic or familial history, inhalation of second-hand smoke, and radiation treatment for breast or chest cancer. Exposure to toxins such as tar, asbestos, nickel, and chromium in the workplace and exposure to radon can also cause lung cancer.
There are two main type of lung cancer – small cell lung cancer and the most common form - non-small cell lung cancer.
A cough that doesn’t go away or a change in a long-term cough
Feeling short of breath or wheezing
Repeated chest infections that won’t go away even after antibiotics
Coughing up blood-stained phlegm
Pain in your chest, especially when you cough or breathe in
Feeling more tired than usual and/or unexplained weight loss
Hoarse voice, problems swallowing or swelling in the face or neck
As with all cancers, getting tested and diagnosed as early as possible increases your chances of survival.
Since our establishment in 2004, Cromos Pharma has conducted dozens of oncology clinical studies involving the participation of thousands of patients across our regions including Central and Eastern Europe. These studies have focused on a range of areas from finding innovative targeted therapies, to biosimilar and generic studies, aimed at offering wider access to novel treatments.
Cromos Pharma offers a flexible oncology model to international sponsors, focused on optimized study design combined with rapid patient enrollment, to accelerate high quality data results. The Cromos Pharma approach focuses on:
Cromos Pharma is a US-based international contract research organization with 16 years' experience in delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic areas. Our expert team boasts wide-ranging expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
From studies in biosimilars and generics to successfully managing oncology, neurology, and dermatology clinical trials, our team provides full service solutions to international pharma and biotech in high recruiting regions, with high quality data assured.
Established in 2004, Cromos Pharma has strong regional experience in Central and Eastern Europe, supported by an extensive network of offices. Its international HQ is in Portland, Oregon, USA.
Throughout March we have been highlighting colorectal cancer, the amazing teams of researchers who are continuously fighting this disease, as well as the millions of patients and families who have been deeply affected by this silent killer. To close out this month of awareness-raising we want to introduce you to a real-life hero and colon cancer survivor - Arlene.
March is Colorectal Cancer Awareness Month. Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide according to 2020 figures from the Global Cancer Observatory.
Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.
Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.